EpicentRx

#AI / data analytics / healthtech / informatics #Anti-inflammatory #Artificial intelligence (AI) #Cancer research #Covid-19 #EpicentRx #Immunology / Virology & Vaccines #Oncology #Polypharmacologic #Precision medicine #Protein binders #Therapeutic targets

New podcast on the significance of drug repurposing

This is the latest episode of the free DDW narrated podcast, titled “Why drug repurposing is so significant for drug discovery” which covers three written for Volume 24 – Issue 1, Winter 2022/2023 of DDW. They are called: AI use in repurposing drugs for Covid-19 and RRx-001: Jack… Read More

#News

#Chemotherapy #EpicentRx #FDA #Head and neck cancer #Oncology #Phase II trial

US FDA fast-tracks drug to prevent severe chemotherapy side effect

The US Food and Drug Administration (FDA) has granted Fast Track Designation to RRx-001 for the prevention/attenuation of severe oral mucositis in chemotherapy and radiation-treated head and neck cancer patients. The FDA also accepted the company’s Investigational New Drug (IND) application to initiate a follow-on Phase… Read More

#News #Regulatory

#Anti-inflammatory #Cancer research #EpicentRx #Oncology #Polypharmacologic #Precision medicine #Protein binders #Therapeutic targets

RRx-001: Jack of all trades, master of…many

Listen to this article on the DDW podcast: Bryan Oronsky, Chief Development Officer at EpicentRx, discusses how one drug sourced from the defense and aerospace industry, could have many potential disese targets. Introduction The term “dilettante”, at least in English, connotes a sloppy bungler, a smatterer, a… Read More

#Exclusive Content